牛牛AI助理已提取核心訊息
Richard A. Colvin, Chief Medical Officer of bluebird bio, Inc., completed a sale of 597 shares of common stock on January 5, 2024. The transaction was carried out on the open market with the shares sold at a price of $1.415 each. Following the sale, Colvin's direct holdings in the company amount to 125,138 shares. The total value of the shares disposed of is approximately $844.76.
Richard A. Colvin, Chief Medical Officer of bluebird bio, Inc., completed a sale of 597 shares of common stock on January 5, 2024. The transaction was carried out on the open market with the shares sold at a price of $1.415 each. Following the sale, Colvin's direct holdings in the company amount to 125,138 shares. The total value of the shares disposed of is approximately $844.76.
藍鳥生物公司首席醫學官理查德·科爾文於2024年1月5日完成了597股普通股的出售。該交易在公開市場上進行，股票以每股1.415美元的價格出售。出售後，科爾文在該公司的直接持股量爲125,138股股票。出售的股票的總價值約爲844.76美元。
藍鳥生物公司首席醫學官理查德·科爾文於2024年1月5日完成了597股普通股的出售。該交易在公開市場上進行，股票以每股1.415美元的價格出售。出售後，科爾文在該公司的直接持股量爲125,138股股票。出售的股票的總價值約爲844.76美元。
有用
沒用